MedTrace Logo

CNCMT：a Multi-center, Prospective, Single-arm Study

NCT06714084 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-12-03

No results posted yet for this study

Summary

To evaluate the safety and efficacy of Cadonilimab in neoadjuvant chemotherapy and maintenance therapy for high-risk advanced cervical cancer receiving concurrent chemoradiotherapy

Conditions

  • Locally Advanced Cervical Cancer
  • PD1
  • CTLA4

Interventions

DRUG

Neoadjuvant Chemotherapy (NACT)

Two cycles of carbonilumab plus TP regimen neoadjuvant chemotherapy will be implemented to patients with advanced cervical cancer

DRUG

maintenance therapy

one years of maintenance therapy with carbonilumab alone will be implemented to patients with advanced cervical cancer receiving standard concurrent chemoradiotherapy

Sponsors & Collaborators

  • Yichang Central People's Hospital

    collaborator OTHER

  • Akeso Pharmaceuticals, Inc.

    collaborator OTHER

  • Hubei Cancer Hospital

    lead OTHER

Principal Investigators

  • HUANG YI, Master's degree

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-08
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06714084 on ClinicalTrials.gov